drug
ribupatide
Phase 3updated 5mo agoby $KLRA Kailera Therapeutics, Inc.
Phase 3community read0 votes
indications
indications
Type 2 DiabetesObesity
all catalysts(0)
nothing on the calendar yet
Trials studying ribupatide
- phase3Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- phase3Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- phase3A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis
- phase2Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
News(4)
- Chutes & Ladders—Former Legend CEO lands at K2Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed…fiercebiotech · 1mo ago
- Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotechJennifer Doudna–founded Scribe Therapeutics intends to use the proceeds from the public offering—the first for a gene editing outfit in over two years—to support development of its epigenetic silen…biospace · 2mo ago
- Kailera says obesity pill succeeds in late-stage trial in ChinaThe drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.biopharma_dive · 2mo ago
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.biopharma_dive · 5mo ago
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that